|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer.
|
26160848 |
2015 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the cluster drawn by the two mutations of V600E and E542K showed that all samples with those mutations belonged to the right-sided colon cancer group.
|
29556349 |
2018 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data suggest that the BRAF V600E mutation is not the target gene for abnormal MMR in carcinogenesis in patients with sporadic endometrial cancer, unlike in colon cancer.
|
19424571 |
2009 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
We used a shRNA-based genetic screen focused on genes upregulated in BRAF(V600E) CCs to identify vulnerabilities of this tumor subtype that might be exploited therapeutically.
|
27058664 |
2016 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.
|
18519771 |
2008 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated the role of BRAF activating mutation (BRAF-V600E) in colorectal tumourigenesis by studying the effects of forced expression of BRAF-V600E in the 'normal' colon epithelial NCM460 cell line and by targeting endogenous BRAF-V600E in MSI-High (MSI-H) colon cancer cell lines.
|
17427169 |
2007 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that the BRAF V600E mutation in microsatellite-stable colon cancer is associated with a significantly poorer survival in stages 2 to 4 colon cancer but has no effect on the excellent prognosis of microsatellite-unstable tumors.
|
16024606 |
2005 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract Cancers) clinical trial were used to assess differential gene expression between c.1799T>A (p.V600E) BRAF mutant and non-BRAF, non-KRAS mutant cancers (double wild type) and to construct a gene expression-based classifier for detecting BRAF mutant samples with high sensitivity.
|
22393095 |
2012 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Female patients and older group harbored a higher KRAS mutation (P = 0.018 and P = 0.031, respectively); BRAF (V600E) mutation showed a higher frequency in colon cancer and poor differentiation tumors (P = 0.020 and P = 0.030, respectively); proximal tumors appeared a higher PIK3CA mutation (P<0.001) and distant metastatic tumors shared a higher NRAS mutation (P = 0.010).
|
24339949 |
2013 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.
|
28951457 |
2017 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
The mutational status of KRAS and BRAF(V600E) oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses.
|
26872400 |
2016 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sorafenib and cetuximab therapy led to a mixed radiographic response with some areas showing dramatic improvement and other areas showing stable disease over a 7-month period which is a notably long period of progression-free survival for V600E BRAF mutated colon cancer.
|
23792568 |
2013 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR).
|
24670642 |
2014 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
We reproducibly associate higher expression of the ligand-receptor axis of TFF2 and CXCR4 with BRAF V600E-mutant colon cancer (P = 3.0 × 10(-3) and 0.077, respectively for TCGA; P = 3.0 × 10(-8) and 5.1 × 10(-7) for CIT).
|
25899003 |
2015 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients.
|
25636897 |
2015 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers with both vemurafenib and EGFR inhibitors is worth clinical evaluation.
|
23074264 |
2012 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
|
31185985 |
2019 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, an oncogenic V600E hotspot mutation within BRAF, a kinase encoding gene from the RAS/RAF/MAPK pathway, has been found to be associated with sporadic MSI-H colon cancer, but its association with HNPCC remains to be further clarified.
|
15342696 |
2004 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mutations, and the CpG island methylator phenotype (CIMP) in colon cancer have not been explored.
|
17293392 |
2007 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and hMLH1) were assessed in 1154 cases of colon cancer.
|
17096326 |
2007 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Colon cancers from 2008 to 2012 tested by pyrosequencing for BRAF V600E mutation were selected.
|
23650027 |
2013 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147).
|
26160882 |
2015 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
In microsatellite stable tumors, homozygous carriers of the G39E polymorphism had an increased risk of CIMP+ colon cancer (odds ratio (OR) 2.2, 95% confidence interval (CI) 1.1, 4.2) and BRAF V600E mutation (OR 3.1, 95% CI 1.01, 9.7) in a case-control comparison.
|
19582761 |
2009 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear.
|
30872078 |
2019 |
|
rs113488022
|
|
Malignant tumor of colon
|
|
0.100 |
GeneticVariation
|
BEFREE |
A colon cancer cell line with RNF43-G659Vfs*41 and BRAF-V600E mutations was sensitive to activation of Wnt/β-catenin signaling.
|
31811196 |
2019 |